Carl M. Gay

Carl M. Gay is an Assistant Professor at The University of Texas MD Anderson Cancer Center. His research focuses on thoracic oncology, specifically the molecular biology of small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). His recent work investigates circulating tumor DNA methylation for treatment monitoring and outcome prediction, including liquid biopsy correlates from the BRIGHTSTAR trial in ALK-rearranged NSCLC. He also explores antibody-drug conjugates targeting HER2 and TROP2 in SCLC, alongside strategies to overcome resistance to topoisomerase I inhibitor payloads. Additional interests include tumor cell surface targeting in high-grade neuroendocrine carcinomas and intracranial responses to novel immunotherapies.